MedTrace Logo

Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

NCT04520035 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-20

No results posted yet for this study

Summary

A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival

Conditions

  • PFS

Interventions

DRUG

camrelizumab

Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles

DRUG

Paclitaxel

Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles

DRUG

Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520035 on ClinicalTrials.gov